benzarubicin
Pre-clinical- Indications
- Veterinary cancers
Company intelligence / Profile preview
Paradox Pharmaceuticals Inc.
Memphis, Tennessee, United Statesparadoxpharma.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Developing benzarubicin as a lead veterinary drug that bypasses drug-resistance mechanisms in tumors and is non-cardiotoxic
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesanthracycline antitumor agents
- Industry
- Veterinary
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Cumberland Pharmaceuticals (licensing partner for pivarubicin development)
Beyond the preview
Go deeper on Paradox Pharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Paradox Pharmaceuticals Inc..